reference/9254595

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9254595

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	1028
issn	0770-3198 1434-9949
issueIdentifier	8
pageRange	1021-1028
publicationName	Clinical Rheumatology
startingPage	1021
bibliographicCitation	van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clinical Rheumatology. 2008 Mar 19;27(8):1021–8. doi: 10.1007/s10067-008-0866-4.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43c1a80e1879e4d989dd7da3ba120eaa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c644f4628073e1756a0a936a5ef831d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c702a1aaef7821f3b49f29ec2bdec71 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d41c0867edcdc81926f7aa2c2b6737b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fed22c7b1a13318c0e58a7ec0e6f4ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_912e1ab5c44ad240350a3b364654a39c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_64f2537b359470b77521e1f26175c993 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88e22277eab4657f475fa1dfc6e2097d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b2636e531a47163e230b32755175625
date	2008-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/18350329 https://doi.org/10.1007/s10067-008-0866-4 https://pubmed.ncbi.nlm.nih.gov/PMC2468311
isPartOf	https://portal.issn.org/resource/ISSN/0770-3198 https://portal.issn.org/resource/ISSN/1434-9949 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3063
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
discusses	http://id.nlm.nih.gov/mesh/M0422769 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001352 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0282056 http://id.nlm.nih.gov/mesh/M0022150
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9109 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6969 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8214

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129094391 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129066678 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Total number of triples: 42.